HuagongsheHuagongshe Chemistry Print Report · For research reference only
Estramustine
Alestramustine · LEO 275 · Estracty · NSC89201 · NSC 89201 · NSC-89201 · Estamustine · Estramustin
Identifiers & Physical Properties
| CAS No. | 2998-57-4 |
|---|---|
| Molecular formula | C23H31Cl2NO3 |
| Average molar mass | 440.4 g/mol |
| Monoisotopic mass | 439.16809921 g/mol |
| SMILES | C[C@]12CC[C@@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@H]3[C@@H]1CC[C@@H]2O |
| InChIKey | FRPJXPJMRWBBIH-RBRWEJTLSA-N |
| PubChem CID | 259331 |
| ChEMBL | CHEMBL1575 |
| ChEBI | CHEBI:4868 |
| EC No. | 221-076-3 |
| DTXSID | DTXSID8046458 |
Chemical & Physical Properties
| XLogP | 4 |
|---|---|
| Topological polar surface area | 49.8 |
| Hydrogen bond donors | 1 |
| Hydrogen bond acceptors | 3 |
| Rotatable bonds | 6 |
| Heavy atoms | 29 |
| Formal charge | 0 |
| Complexity | 584 |
| Drugs | Pharmaceuticals -> Listed in ZINC15 |
| Lipids | Lipids -> Sterol Lipids [ST] -> Steroids [ST02] -> C18 steroids (estrogens) and derivatives [ST0201] |
| LogP (partition coefficient) | 5.7 |
| Solubility | 3.85e-04 g/L1mg/L(30 ºC) |
| Endocrine Disruptors | Potential endocrine disrupting compound |
| Melting point | 104.5 °C104-105° |
| Physical Description | Solid |
| alpha | D20 +50° (in dioxane) |
| Boiling point | 565.8±50.0 °C(Predicted) |
| Density | 1.253±0.06 g/cm3(Predicted) |
| Storage conditions | Store at -20°C |
| Physical state | Solid |
| pKa (acidity coefficient) | 15.05±0.40(Predicted) |
| Color | White to off-white |
| InChIKey | FRPJXPJMRWBBIH-SZZXFXARNA-N |
| SMILES | [C@@]12([H])CCC3C=C(OC(=O)N(CCCl)CCCl)C=CC=3[C@@]1([H])CC[C@]1(C)[C@H](CC[C@@]21[H])O |&1:0,20,24,26,29,r| |
| CAS DataBase Reference | 2998-57-4(CAS DataBase Reference) |
| FDA UNII | 35LT29625A |
| NCI Dictionary of Cancer Terms | estramustine |
| ATC code | L01XX11 |
| GHS pictogram | GHS07 |
| Signal word | Warning |
| GHS hazard statements | H302-H315-H319-H335 |
| GHS precautionary statements | P261-P305+P351+P338 |
Safety & Regulations
| GHS classification | This chemical does not meet GHS hazard criteria for 3% (1 of 33) of reports.DangerH351 (93.9%): Suspected of causing cancer [Warning Carcinogenicity]P203, P280, P318, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 33 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Hazard Classes and Categories | Carc. 2 (93.9%) |
| Drug Induced Liver Injury | Drug-Induced Liver Injury Severity and Toxicity (DILIst)estramustineDILI PositiveOralDOI:10.1016/j.drudis.2019.09.022 |
| Signal word | Warning |
| GHS pictogram | GHS07 |
| GHS hazard statements | H302-H315-H319-H335 |
| GHS precautionary statements | P261-P305+P351+P338 |
Applications & Uses
Uses
Antineoplastic.
Uses
Estradiol 3-[N,N-Bis(2-chloroethyl)carbamate] is used treatment of breast cancer. Also used in the treatment of prostate cancer.